Abstract | BACKGROUND: OBJECTIVES: METHODS: Data were obtained from a prospective, longitudinal paediatric psoriasis registry, called Child-CAPTURE. Severity was assessed using the Psoriasis Area and Severity Index (PASI) and body surface area (BSA). The Children's Dermatology Life Quality Index (CDLQI) was used to assess QoL and visual analogue scores (VAS) for pain and itch were collected. For safety data the number of (serious) adverse events was recorded. RESULTS: Seventy-three patients (mean age 10·8 years, range 3-18) were treated for a median time of 35·0 weeks (range 1·0-176·0). At week 12, mean PASI decreased 15·4% (from 5·2 to 4·4), BSA barely changed, and median CDLQI decreased significantly from 5·5 to 4·0. VAS scores for pain and itch declined. At week 24, mean PASI decreased to 4·3 (17·3%). No related serious adverse events were observed. CONCLUSIONS:
|
Authors | M J van Geel, K Mul, A M Oostveen, P C M van de Kerkhof, E M G J de Jong, M M B Seyger |
Journal | The British journal of dermatology
(Br J Dermatol)
Vol. 171
Issue 2
Pg. 363-9
(Aug 2014)
ISSN: 1365-2133 [Electronic] England |
PMID | 24593129
(Publication Type: Journal Article, Observational Study, Research Support, Non-U.S. Gov't)
|
Copyright | © 2014 British Association of Dermatologists. |
Chemical References |
- Dermatologic Agents
- Drug Combinations
- Ointments
- calcipotriene
- betamethasone-17,21-dipropionate
- Betamethasone
- Calcitriol
|
Topics |
- Adolescent
- Betamethasone
(administration & dosage, adverse effects, analogs & derivatives)
- Calcitriol
(administration & dosage, adverse effects, analogs & derivatives)
- Child
- Child, Preschool
- Dermatologic Agents
(administration & dosage, adverse effects)
- Drug Combinations
- Female
- Humans
- Male
- Ointments
- Prospective Studies
- Psoriasis
(drug therapy)
- Quality of Life
- Treatment Outcome
|